Arya Farahmand, MD
Neurology · Nashua, NHNPI 1598751521
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 30.0% of the total. Reporting peaked in 2024 at $611 and has fallen 71.7% since, to $173 in 2025.
Across 111 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$645
- Lundbeck LLC$240
- Supernus Pharmaceuticals, Inc.$209
- GE HealthCare$143
- Greenwich Biosciences, Inc.$129
- SK Life Science, Inc.$119
- plus $668 from 15 others
Across 12 payments — averaging $7134.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$67K
- Sage Therapeutics, LLC$19K
What the payments were for
- Food & beverage$2,144100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $645 |
| Lundbeck LLC | 14 | $240 |
| Supernus Pharmaceuticals, Inc. | 24 | $209 |
| GE HealthCare | 8 | $143 |
| Greenwich Biosciences, Inc. | 4 | $129 |
| SK Life Science, Inc. | 5 | $119 |
| EMD Serono, Inc. | 4 | $103 |
| Sunovion Pharmaceuticals Inc. | 4 | $82 |
| Kyowa Kirin, Inc. | 4 | $74 |
| Biohaven Pharmaceuticals, Inc. | 2 | $45 |
| Pfizer | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 1 | $44 |
| Biogen | 2 | $41 |
| Livanova USA, Inc. | 2 | $38 |
| Novartis | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $35 |
| Harmony Biosciences LLC | 1 | $29 |
| Akcea Therapeutics, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Neuropace, Inc. | 1 | $20 |
How this compares
$2,153 in reported general payments places this provider in the 75th percentile of 92 neurology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $59,470 |
| LamictalLamotrigine | 22 | $51,582 |
| XcopriCenobamate | 35 | $50,584 |
| BriviactBrivaracetam | 17 | $31,399 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $27,572 |
| GlatopaGlatiramer Acetate | 15 | $22,908 |
| QuliptaAtogepant | 15 | $16,477 |
| Glatiramer Acetate | 13 | $16,224 |
| Lacosamide | 92 | $14,165 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,581 |
| UbrelvyUbrogepant | 13 | $10,784 |
| Levetiracetam | 356 | $10,449 |
| Lamotrigine | 193 | $8,692 |
| NeurontinGabapentin | 12 | $7,415 |
| Memantine Hcl ErMemantine Hcl | 143 | $7,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $119 | $50,58435 claims |
| AbbVieQulipta, Ubrelvy | $645 | $27,26128 claims |
| PfizerNurtec Odt, Dilantin | $45 | $17,27534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 neurology providers in New Hampshire.
Other neurology in Nashua
- Jacob KaufmanNashua$17K
- Andreja PackardNashua$4K
- Saeedeh AzaryNashua$1K
- Khawaja RahmanNashua$482
- Sachin DaveNashua$187
- Ann CabotManchester$622K
- Oliver PhillipsLebanon$50K
- Andrew PachnerLebanon$31K
- Jeffrey RindDerry$27K
- Uladzimir LuchanokDerry$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.